Radioactive drug targets advanced prostate cancer in first human trial

NCT ID NCT04644770

Summary

This early-stage study is testing a new radioactive antibody drug called JNJ-69086420 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The main goal is to find the safest and most effective dose by monitoring side effects in 144 participants. Researchers will also check if the drug shows early signs of slowing cancer growth by measuring prostate-specific antigen (PSA) levels and tumor changes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Case Western Reserve University

    Cleveland, Ohio, 44106, United States

  • City of Hope

    Duarte, California, 91010, United States

  • East Jefferson General Hospital

    Metairie, Louisiana, 70006, United States

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Tulane University Hospital & Clinics

    New Orleans, Louisiana, 70112, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • XCancer Omaha / Urology Cancer Center

    Omaha, Nebraska, 68130, United States

Conditions

Explore the condition pages connected to this study.